
Precision Medicine in Oncology®
Latest News
Latest Videos

CME Content
More News

Dr. Giorgio Scagliotti from the University of Turin on Tailored Treatment and the Cancer Genome

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Treatment

Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors

Dr. Giorgio V. Scagliotti from the University of Turin Discusses the Future of Lung Cancer Therapy

Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors

Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67

Johan Lennartsson's research focuses on platelet-derived growth factor receptor (PDGFR) and mitogen-activated protein kinase (MAPK) signaling in normal physiology and cancer.

The breadth of the stem cell factor (SCF)/ KIT signaling pathway oncogenic functions and potential role as a therapeutic target are just now becoming clear.

Dr. Debu Tripathy from the USC Norris Cancer Center on Connecting Markers to Clinical Outcomes

Established in 1970 as a small clinic for cancer patients, the Georgetown Lombardi Comprehensive Cancer Center was named for football coach Vince Lombardi, who was treated for cancer at Georgetown University Hospital.

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Biomarkers

Dr. Matthew J. Ellis from Washington University Discusses the Future of the PI3-Kinase Pathway

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67

It's hard to tell which moves more quickly: Edith Perez's feet, or her mind.

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

Dr. Debu Tripathy from UC Norris Cancer Center Discusses HER2 Targeted Therapies

Biological markers that help clinicians choose which treatment options to pursue for particular patients are attracting increased research interest.

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score













































